THIS FROM AI , AVION HAS NO RIGHTS28 Oct 2025 21:55
ImmuPharma justified a new patent for its drug candidate P140 (marketed as Lupuzor™ for lupus) based on three key discoveries, which go far beyond a simple formulation change. The new patent, filed in September 2025, covers an expanded application of the P140 compound, including a novel diagnostic method for identifying a new category of autoimmune disease.
The basis for the new patent is the result of extensive research conducted by ImmuPharma, which identified the following:
Identification of "Type M" immune disorder: Researchers identified a newly defined sub-type of autoimmune disease that they named "Type M." P140 was found to be especially effective for patients with this specific disorder.
Discovery of a novel diagnostic test: The company developed a companion diagnostic test to identify patients with the Type M immune disorder who would be most responsive to P140 treatment, or "super-responders". This precision medicine approach allows for more targeted treatment and potentially better trial outcomes.
Refined mechanism of action (MOA): The research confirmed that P140 works as an "immunormalizer," restoring the balance of the immune system rather than suppressing it. This distinct MOA is a significant departure from older immunosuppressant therapies, which have many side effects.
Broader commercial implications
This strategy allows ImmuPharma to seek new partnerships and expand the scope of P140 beyond its initial focus on lupus.
The new patent, which can provide 20 years of commercial exclusivity, covers the use of P140 for up to 50 different autoimmune diseases.
This is separate from the company's prior agreement with Avion Pharmaceuticals, which was specific to Lupuzor™ for treating lupus in the U.S.
Sign In
Follow the stocks
